i&i Biotech Fund — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
Enzyreenzyre.comNov 2022
Enzyre develops a handheld diagnostic device that performs multiple blood coagulation assays in parallel to identify bleeding causes at the point of care.
BiotechDeep TechDigital HealthHealthtechMedical DevicesEindhoven, NL
Wim van den Broek(CEO)inWaander(CSO)
Co-investorsNovalis BiotechOost NLTakeda Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Celeris Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
